Navigation Links
Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
Date:12/23/2010

FRAZER, Pa., Dec. 23, 2010 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that its Board of Directors has appointed J. Kevin Buchi as Chief Executive Officer and a member of the company's Board. The Board will address the role of company Chairman in the future. William P. Egan will continue to serve as Cephalon's independent Presiding Director.

"Kevin is an experienced pharmaceutical executive who has been involved in every aspect of running our business," said Mr. Egan. "Over the course of many years, Kevin worked closely with Frank Baldino, Jr., to create the company that we know today, and he has the passion, leadership skills, organizational abilities and unwavering commitment to patients that are critical to ensuring Cephalon's continued growth and success. He is the clear choice to lead our company."  

Mr. Buchi, who has been with Cephalon for almost 20 years, assumed day-to-day chief executive responsibilities for the company in August 2010. He previously served as a member of the Cephalon executive management team in the roles of Chief Operating Officer and Chief Financial Officer. Additionally, for the last seven years, he has led the business development function with responsibility for mergers, acquisitions and in-licensing of products.

Commenting on his appointment as CEO, Mr. Buchi said, "I am honored to be named Chief Executive Officer and to continue the work of Frank Baldino. I had the privilege to work with Frank as we crafted the strategy for leading and growing Cephalon. I intend to continue the same strategic course for the company." Mr. Buchi added, "Cephalon is an extraordinary company with one of the most robust pipelines in the industry focused on patients suffering from rare disorders and diseases for which there are no cures. We have expanded our global footprint dramatically in the last few years. I am confident that our diverse product portfolio, rich pipeline and global presence position us well for long-term growth and success."

About J. Kevin BuchiJ. Kevin Buchi was appointed Chief Operating Officer of Cephalon in 2010. In this role, he managed the company's global sales and marketing functions, as well as product manufacturing, business development and investor relations.  From 1996 to 2009, Mr. Buchi served as Chief Financial Officer and, from 2004, head of business development for the company. At various times in his career at Cephalon, Mr. Buchi has had oversight of corporate finance, accounting, information systems, facilities, human resources and administration. Mr. Buchi joined Cephalon in 1991 as controller.

Mr. Buchi graduated from Cornell University with a Bachelor of Arts degree in chemistry. He was a synthetic organic chemist for the Eastman Kodak Company before going on to obtain a master's degree in management from the J.L. Kellogg Graduate School of Management at Northwestern University. He worked for a large public accounting firm before beginning his career in the pharmaceutical industry with E.I. du Pont de Nemours and Company in 1983. He is a certified public accountant.

About Cephalon, Inc.Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries. More information on Cephalon and its products is available at http://www.cephalon.com/

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion. Contacts:MediaFritz BittenbenderVice President, Public AffairsT: 610-883-5855C: 610-457-7041fbittenb@cephalon.comChip MerrittVice President, Investor RelationsT: 610-738-6376cmerritt@cephalon.comJoseph MarczelySenior Investor Relations AnalystT: 610-883-5894jmarczel@cephalon.com
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cephalon to Webcast Investor Day
2. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
3. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
4. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
5. Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
6. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
7. Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.
8. Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign Position
9. Cephalon Provides Update on Regulatory Review of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
11. Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million and ... operations Second-quarter 2017 Branded ... Second-quarter 2017 Sterile Injectables ... Second-quarter 2017 adjusted diluted earnings per ... $0.93 Second-quarter 2017 reported ...
(Date:8/7/2017)... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ...  All comparisons, unless otherwise noted, are to the quarter ended ... Second Quarter 2017 Highlights include: Revenue ... 3.5% Total prescriptions dispensed of 220,000, compared ... 7.6% Gross profit per prescription dispensed ...
(Date:8/3/2017)... Aug. 3, 2017  Opioid addiction and other drugs ... healthcare costs and threatening outcomes, were problems taken on ... IVD industry that support them, met this week. This ... said that drugs of abuse, procalcitonin and acute kidney ... the organization,s 69th meeting in San Diego, ...
Breaking Medicine Technology:
(Date:8/16/2017)... Houston, TX (PRWEB) , ... August 16, 2017 , ... ... named as a Castle Connolly 2017 Top Doctor. The annual list identifies the nation’s ... row that Dr. Vitenas has made it to the top of Castle Connolly’s coveted ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of Infection ... reprocessing cycle, both between patient procedures and before storage, is a requisite practice ... important to the prevention of disease transmission and nosocomial infection as cleaning and ...
(Date:8/16/2017)... ... August 16, 2017 , ... Richard Strawn’s new book ... the time of a cancer diagnosis, surgery and recovery, the Psalms provided encouragement ... many ways God shows love to those who are sick., Surgical Psalms contains ...
(Date:8/16/2017)... NJ (PRWEB) , ... August 16, 2017 , ... ... is offering an opportunity for men and women to train as hospice ... families dealing with life-limiting illness. For over 30 years, the agency has trained ...
(Date:8/16/2017)... ... 16, 2017 , ... Rollon Skin Care Ltd., ... recently announced the launch of two new skincare products, Prache Antiaging Cream and ... expensive plastic surgery or in-patient cosmetic dermatological procedures. , “Prache Antiaging Cream and ...
Breaking Medicine News(10 mins):